If you didn’t know already, my story today provided a sense of the troubles facing the biotechnology industry theses days. But I didn’t give you the complete picture, which is very ugly.

Here is a rundown of the industry’s recent financial performance courtesy of Bio, the national industry association:

  • 120 publicly traded biotech companies (30 percent) are now trading with less than six months of cash on hand. This represents a jump of 90 percent more companies that have less than six months cash on hand versus 2007.
  • 180 publicly traded biotech companies (45 percent) have less than one year of cash remaining, which is two-thirds more than in 2007.
  • Only 10 percent of the 370 publicly traded U.S. biotech companies have positive income.
  • By comparison with 2007, funds raised from IPOs in 2008 fell 97 percent, and follow-on/secondary offerings fell 56 percent. Total capital raised by the industry in 2008 fell by 55 percent versus 2007.
  • In 2006, 32 life sciences companies raised $1.7 billion through IPOs. In

    2007, 41 raised $1.9 billion. In 2008 there was only one IPO in the country; it raised $5.8 million.

  • There were 19 biotech IPOs withdrawn in 2008, and six biotech bankruptcies in 2008.
  • Stock Performance in 2008:
    All U.S. biotech stock performance: Mean -49 percent, Median -61 percent ;
    Small US biotech stock performance: Mean -51 percent, Median -64 percent
    Large U.S. biotech stock performance: Mean -26 percent, Median -30 percent (Large is defined as greater than a $1 billion market cap on Jan. 1, 2008)
    87 percent of U.S. biotech stocks have lost value in 2008
  • More than 80 companies laid off more than 5,000 employees in 2008, and 34

    biotech companies laid-off 10 percent or more of their workforce since September,


  • From September 2008 to January 2009, more than 24 companies shelved promising drug development programs in a number of therapeutic areas including: Alzheimer’s, Multiple Sclerosis, diabetes and various cancers.

Leave a comment

We expect all commenters to be constructive and civil. We reserve the right to delete comments without explanation. You are welcome to flag comments to us. You are welcome to submit an opinion piece for our editors to review.

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.